AUTHORS
Anna Oh, PhD, MPH, RN, Alfonso Molina Jr, MD, MPH2, Gabriel Mannis I, MD3, William Shomali, MD4, Michaela Liedtke, MD5, Jason Gotlib, MD,MS6, Tait D Shanafelt, MD7, Bita Fakhri, MD, MPH8
AFFILIATIONS
1 Stanford University, Stanford, California, United States
2 Stanford University, Stanford, California, United States
3 Stanford University, Stanford, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 Stanford University, Stanford, California, United States
8 Stanford University, Stanford, California, United States
ABSTRACT
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are related B-cell malignancies that represent the most common form of adult leukemia. Although clinical trials have advanced novel therapeutic options, unequal participation across sociodemographic backgrounds can limit the generalizability of trial findings to a broader patient population.
This study evaluated demographic characteristics of CLL/SLL clinical trial participants at a National Cancer Institute (NCI)-designated Cancer Center in Northern California from 2012 to 2024 and compared these characteristics with national and regional prevalence estimates from the NCI’s Surveillance, Epidemiology, and End Results (SEER) database. Representation was assessed using participation-to-prevalence ratios (PPRs) comparing trial demographics with national and regional estimates. PPR compares a group’s representation among participants with its representation in the eligible/reference population: 0.8-1.2: generally considered proportional representation, <0.8: underrepresentation, and >1.2: overrepresentation.
Between 2012 and 2024, a total of 212 unique patients enrolled in 30 CLL clinical trials at our institution. Thirty-two participants (15%) enrolled in multiple trials, with a maximum of four enrollments per patient, resulting in 280 total trial enrollments. The median age at first enrollment was 66.6 years (range, 21.5-87.9), with 136 (64%) identifying as male. The racial/ethnic distribution included 11 (5%) non-Hispanic Asian, 5 (2%) non-Hispanic Black, 5 (2%) Hispanic alone or in combination with another race category, 14 (7%) non-Hispanic other/bi-/multi-racial, and 174 (82%) non-Hispanic White participants. The majority (n=207, 98%) reporting English as their primary language. Insurance coverage was primarily Medicare (114, 54%), private insurance (47, 22%), and managed care (43, 20%). Insurance data reflected only primary coverage, as information regarding secondary or supplemental insurance was not available. Most trial participants (115, 54%) resided in the nine-county Bay Area catchment area, with a median estimated driving distance of 50 miles (80.5 kilometers) from our institution’s Cancer Center (range, 2.0-3000.6).
PPRs analyses comparing trial participant demographics with SEER prevalence data indicated enrollment gaps across different sex and race/ethnic groups. Compared with regional Northern California SEER CLL prevalence, clinical trial enrollment was low for all racial and ethnic groups. The PPR for non-Hispanic Asian males was 0.30 (3% vs. 9%), while the PPR for non-Hispanic Asian females was 0.24 (2% vs. 10%). Non-Hispanic White participants also enrolled below expected rates, with females (31% vs. 79%, PPR=0.39) showing greater enrollment gaps than males (51% vs. 80%, PPR=0.64). Small sample sizes among Hispanic females and non-Hispanic Black females (n<5) prevented PPR analyses for these groups.
Comparisons with national SEER data showed similar patterns. Similar to the regional comparison, small sample sizes among Hispanic females and non-Hispanic Black females prevented PPR analyses for these groups. Among groups with sufficient representation, non-Hispanic White females enrolled at lower rates (31% vs. 83%, PPR=0.37) than non-Hispanic White males (51% vs. 84%, PPR=0.61). Non-Hispanic Asian males (3% vs. 2%, PPR=1.17) and Asian females (2% vs. 3%, PPR=0.96) were the only groups who participated at rates close to or above national prevalence estimates.
Compared with national prevalence estimates, the greatest enrollment gaps were among non-Hispanic Black and Hispanic females, while Asian males participated at rates slightly above proportional estimates. Regional comparisons revealed lower representation across most groups. Nearly one-third of participants enrolled in multiple trials, indicating repeated participation among a subset of individuals. These inequitable participation patterns may limit the generalizability of trial findings to a broader patient population and highlight ongoing structural barriers. Efforts to improve equity in clinical trial enrollment should emphasize inclusive recruitment, community engagement, and reduction of logistical and financial barriers.
DISCLOSURES
Anna Oh, PhD, MPH, RN: No relevant conflicts of interest to declare.